tiprankstipranks
TipRanksTop Financial ExpertsInsidersPolaris Venture Management Co. V, L.L.C.

Polaris Venture Management Co. V, L.L.C. Insider Profile

4 Followers
Polaris Venture Management Co. V, L.L.C., Ten Percent Owner at Genocea Biosciences, holds 7.27K shares in Lyra Therapeutics (Ticker: LYRA), holds 3.21M shares in Phreesia (Ticker: PHR), holds 21.33K shares in Cardlytics (Ticker: CDLX). Most recently, Polaris Venture Management Co. V, L.L.C. Bought ― shares of Lyra Therapeutics on May 06, 2020 for an estimated value of 1.00M.
tipranks
Polaris Venture Management Co. V, L.L.C.

Polaris Venture Management Co. V, L.L.C.
Genocea Biosciences (GNCA)
Ten Percent Owner

Ranked #77,247 out of 78,896 Corporate Insiders

Profitable Transactions

26%
5 out of 19 Profitable Transactions

Average Return

-37.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$424M
53.07%
41.16%
2.76%
1.12%
1.88% Others
A breakdown of Polaris Venture Management Co. V, L.L.C.'s holdings

Insider Roles

Fate Therapeutics
(FATE)
Ten Percent Owner
Phreesia
(PHR)
Ten Percent Owner
X4 Pharmaceuticals
(XFOR)
Ten Percent Owner
Genocea Biosciences
(GNCA)
Ten Percent Owner
+5 other positions
Roles that Polaris Venture Management Co. V, L.L.C. holds in companies

Most Profitable Insider Trade

Stock:
Ocular Therapeutix
(OCUL)
Rating:Informative Sell
Date:Feb 04, 2015 - Feb 04, 2016
Return:+79.60%
The most profitable trade made by Polaris Venture Management Co. V, L.L.C.

Polaris Venture Management Co. V, L.L.C.'s Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Genocea Biosciences
Jun 19, 2015
Ten Percent Owner
Informative Sell
391.21K
$4.76M
X4 Pharmaceuticals
Nov 20, 2017
Ten Percent Owner
Uninformative Buy
$11.71M
Cardlytics
Jul 17, 2019
Ten Percent Owner
Uninformative Sell
1.90M
$3.05M
Phreesia
Dec 18, 2019
Ten Percent Owner
Informative Sell
8.74M
$174.40M
Lyra Therapeutics
May 06, 2020
Ten Percent Owner
Informative Buy
1.00M
$82.92K
Ocular Therapeutix
Feb 04, 2015
Ten Percent Owner
Informative Sell
14.75M
$405.47K
Fate Therapeutics
Oct 04, 2013
Ten Percent Owner
Uninformative Buy
770.68K
$224.89M
Daré Bioscience
Apr 15, 2014
Ten Percent Owner
Uninformative Buy
4.88M
$4.37M
BINDQ
DNIB Unwind, Inc.
Sep 27, 2013
Informative Buy
390.00K
$292.65K
Trevena
Aug 15, 2014
Ten Percent Owner
Informative Sell
221.68K
$77.83K
List of latest transactions for each holding click on a transaction to see Polaris Venture Management Co. V, L.L.C.'s performance on stock

Polaris Venture Management Co. V, L.L.C. insider profile FAQ

What is the percentage of profitable transactions made by Polaris Venture Management Co. V, L.L.C.?
The percentage of profitable transactions made by Polaris Venture Management Co. V, L.L.C. is 26%.
    What is the average return per transaction made by Polaris Venture Management Co. V, L.L.C.?
    The average return per transaction made by Polaris Venture Management Co. V, L.L.C. is -37.20%.
      What stocks does Polaris Venture Management Co. V, L.L.C. hold?
      Polaris Venture Management Co. V, L.L.C. holds: GNCA, XFOR, CDLX, PHR, LYRA, OCUL, FATE, DARE, BINDQ, TRVN stocks.
        What was Polaris Venture Management Co. V, L.L.C.’s latest transaction?
        Polaris Venture Management Co. V, L.L.C. latest transaction was an Informative Buy of $1.00M.
          What was Polaris Venture Management Co. V, L.L.C.'s most profitable transaction?
          Polaris Venture Management Co. V, L.L.C.’s most profitable transaction was an Informative Sell of OCUL stock on February 4, 2015. The return on the trade was 79.60%.
            What is Polaris Venture Management Co. V, L.L.C.'s role in Genocea Biosciences?
            Polaris Venture Management Co. V, L.L.C.'s role in Genocea Biosciences is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.